2025 ahead ayondo Franchise coming soon
Happy 
xMas Holidays
xMas Holidays
xMas Holidays
|
Achiko AG / Key word(s): Miscellaneous Achiko AG Appoints New Chief Financial Officer Zurich, 7 October 2022: Ad hoc announcement pursuant to Art. 53 LR – Achiko AG (SIX: ACHI; OTCQB: ACHKF; ISIN CH0522213468) (“Achiko”, the “Company”) a healthcare technology company that is developing new innovations and disruptive diagnostic solutions that put people first announced that it has appointed Lars Birkmann as Chief Financial Officer (CFO) as of 5th October 2022, succeeding Adam O’Keeffe as ad interim CFO. Mr Birkmann, 44, has successfully worked in the Swiss life sciences sector for over twenty years and has been involved in all areas of finance from accounting, financial control, treasury, and mergers and acquisitions. He will take over the CFO position at Achiko and join the Company’s Executive Committee. Prior to Achiko, Lars was the CFO at Ender Diagnostics AG (Bern) and before that the CFO for Sensile Medical AG (Olten). Lars has completed his studies in Economics and Study in Law, and a degree in Business from the Business School in Leipzig. He is also a federal expert in European and Swiss VAT law. “We are excited to welcome Lars on board”, said Mr Steven Goh, CEO of Achiko AG. “It’s the start of a process to build an executive team and Board with Swiss representation and is a decisive step towards the Company’s final transformation into becoming a diagnostics and technology company.” ABOUT ACHIKO AG Achiko AG (SIX: ACHI.SW; OTCQB: ACHKF; www.achiko.com) is developing disruptive diagnostic solutions that put people first. The Company’s lead product, AptameX™, is a rapid, reliable Covid-19 test with a companion app, Teman Sehat™, offering a user-friendly digital health passport. AptameX™ and Teman Sehat™ were launched in Indonesia in mid-2021 and AptameX™ received the CE Mark in the European Union in May 2022. The AptameX™ DNA aptamer tests can be rapidly chemically synthesised, are cost-effective, easily scalable and have broad potential across multiple disease areas. Achiko aims to deliver fast, accurate and affordable diagnostic testing for a range of diseases in the rapidly evolving healthcare diagnostics field. Headquartered in Zurich, Achiko has offices in Jakarta, and staff around the world.
ACHIKO AG Switzerland & Global Disclaimer End of Inside Information |
| Language: | English |
| Company: | Achiko AG |
| Tessinerplatz 7 | |
| 8002 Zurich | |
| Switzerland | |
| E-mail: | ir@achiko.com |
| Internet: | https://www.achiko.com/ |
| ISIN: | CH0522213468 |
| Valor: | 48788430 |
| Listed: | SIX Swiss Exchange |
| EQS News ID: | 1458663 |
| End of Announcement | EQS News Service |
|
|
1458663 07-Oct-2022 CET/CEST
P R O D U C T S U G G E S T I O N S
The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.
The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.
If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.
For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.
1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.
